CLLS Cellectis
- 2.990
- 0.0000.00%
- 2.930
- -0.060-2.01%
Cellectis News
Cellectis Announces Leadership Shift in Finance
Cellectis CFO Bing Wang Retires, Interim CFO Appointed
Cellectis S.A (CLLS) said Thursday that Chief Financial Officer Bing Wang has retired from the company with immediate effect. The company has appointed Arthur Stril as interim CFO. Stril joined Cellec
Cellectis SA: Strong Investment and Clinical Progress Signaling a Market Outperform Rating
Cellectis Announces CFO Departure
Cellectis SAys Bing Wang Is Resigning From His Position as CFO With Immediate Effect
Cellectis SAys Bing Wang Is Resigning From His Position as CFO With Immediate Effect
Cellectis Appoints Arthur Stril as Interim Chief Fincl Officer >CLLS
Cellectis Appoints Arthur Stril as Interim Chief Fincl Officer >CLLS
European Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday Trading
European equities traded in the US as American depositary receipts were trending modestly higher Thursday morning, rising 0.25% to 1,364.91 on the S&P Europe Select ADR Index. From continental Europe,
Analysts Offer Insights on Healthcare Companies: Healthequity (HQY), Cellectis SA (CLLS) and Idexx Laboratories (IDXX)
Barclays Remains a Buy on Cellectis SA (CLLS)
Express News | Cellectis Q4 2023 GAAP EPS $(0.64) Misses $(0.26) Estimate, Sales $1.990M Miss $16.263M Estimate
Cellectis Believes Cash Runway Is Extended Into 3Q of 2025 and Will Be Able to Operate for at Least 12 Mos Following Consolidated Fincl Statements
Cellectis Believes Cash Runway Is Extended Into 3Q of 2025 and Will Be Able to Operate for at Least 12 Mos Following Consolidated Fincl Statements
Cellectis 4Q Loss/Shr 64c >CLLS
Cellectis 4Q Loss/Shr 64c >CLLS
Press Release: Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023 -- Preliminary results of NATHALI-01 and updated results of BALLI-01 Phase I clinical studies presented at the American
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4%
European equities traded in the US as American depositary receipts were trending higher Friday morning, rising 0.5% to 1,380.32 on the S&P Europe Select ADR Index. With the gain, the index is set to c
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading
European equities traded in the US as American depositary receipts were trending modestly higher Thursday morning, rising 0.24% to 1,364.10 on the S&P Europe Select ADR Index. From continental Europe,
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading
European equities traded in the US as American depositary receipts were trending lower Wednesday morning, declining 0.9% to 1,356.02 on the S&P Europe Select ADR Index. From continental Europe, the ga
Cellectis Unveils Groundbreaking Gene-Editing Advances
Express News | Cellectis To Present Data On TALEN Editing Process At ASGCT Mat 7-11
Cellectis Presents Novel TALEN Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
This novel editing approach might unlock new strategies for the treatment of metabolic and neurological diseasesNon-viral circular ssDNA delivery associated to TALEN gene editing allows high levels of gene
European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading
After closing out last week more than 2% lower, European equities traded in the US as American depositary receipts rebounded Monday morning, rising 1.09% to 1,340.58 on the S&P Europe Select ADR Index
Analysis
Price Target
No Data
